U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07837973) titled 'Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss' on Aug. 31.
Brief Summary: A study of ALV-100 to assess efficacy, safety and tolerability among participants with overweight or obesity who have previously achieved a body weight reduction of >=10% while treated with semaglutide.
Study Start Date: Aug. 10
Study Type: INTERVENTIONAL
Condition:
Overweight , Obesity
Adults
Intervention:
DRUG: ALV-100
Experimental drug
DRUG: Placebo
Volume matched placebo
Recruitment Status: RECRUITING
Sponsor: Alveus Therapeutics, Inc.
Published by HT Digital Content Services with permission from Health Daily D...